Au Revoir Genzyme; Sanofi Stakes Its Claim With $20.1 Billion Upfront And CVRs
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis finally struck a deal to acquire Genzyme for $20.1 billion plus potential future payments, but successfully integrating the company remains the challenge.